Vision - Conquer prostate cancer

Prostate Cancer Cover Image

» Click on Image to View Program Booklet

Prostate cancer is the most commonly diagnosed cancer in men and is the second most common cause of male death from cancer. In 2016, approximately 180,890 men in the U.S. will be diagnosed with prostate cancer and an estimated 26,120 will die from it. In addition, there are major population disparities in prostate cancer incidence and mortality, with African American men experiencing 2.5 times greater risk of prostate cancer death compared to Caucasian men. The Prostate Cancer Research Program prioritizes research that will 1) distinguish aggressive from indolent disease in men newly diagnosed with prostate cancer, 2) develop strategies to prevent progression to lethal prostate cancer, 3) develop effective treatments and address mechanisms of resistance for men with high risk or metastatic prostate cancer, and 4) develop strategies to optimize the physical and mental health of men with prostate cancer. The focus areas for funded research include biomarker development, genetics, imaging, mechanisms of resistance, survivorship and palliative care, therapy, and tumor and microenvironment biology.

Congressional Appropriations

Congressional Appropriations

  • $1.53 billion
  • $90.0 million

Related Videos

The CDMRP Grant Review Process: Maximizing Success

2016 Prostate Cancer IMPaCT Meeting Highlights

Dr. Colin Pritchard

University of Washington
Hypermutation and Genomic Testing for Precision Therapy in Advanced Prostate Cancer

Dr. Himisha Beltran

Weill Cornell Medicine
Divergent Clonal Evolution of Castration Resistant Neuroendocrine Prostate Cancer

news_icon News & Highlights


Conquer prostate cancer


Fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease

Last updated Tuesday, February 20, 2018